In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species.

Antimicrobial Agents and Chemotherapy
J A VazquezJ D Sobel

Abstract

The activity of a new water-soluble pneumocandin, L-733,560, was evaluated with 107 pathogenic strains of Candida and Torulopsis, which included 23 strains with known multi-azole resistance patterns. In vitro evaluation of L-733,560 activity was performed by a broth microdilution method, and the activity was compared with the activities of amphotericin B, fluconazole, ketoconazole, itraconazole, and flucytosine. The mean MICs of L-733,560 were 0.15 microgram/ml for C. lusitaniae, 0.72 microgram/ml for C. parapsilosis, 0.78 micrograms/ml for C. krusei, and 1.25 micrograms/ml for C. guilliermondii. The results indicate that the new antifungal agent L-733,560 demonstrated the best activity with the lowest MICs against C. albicans, T. glabrata, C. tropicalis, and C. kefyr, less activity against C. krusei, C. lusitaniae, and C. parapsilosis, and the least activity against C. guilliermondii. L-733,560 also demonstrated good activity against the various multi-azole-resistant Candida and T. glabrata isolates.

References

Apr 1, 1992·The Journal of Infectious Diseases·J ConlyL Hellman
Nov 1, 1992·Journal of Clinical Microbiology·V SanchezM J Zervos
Dec 11, 1992·Journal of Clinical Microbiology·A Espinel-IngroffM G Rinaldi
Jun 1, 1989·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M S Gelfand
Jul 1, 1989·Mycopathologia·G NobreO Cruz
Dec 3, 1988·Lancet·D W WarnockE W Williams
Jan 1, 1987·Methods in Enzymology·E Cabib, M S Kang
May 1, 1988·The American Journal of Medicine·W G PowderlyG Medoff
Sep 1, 1985·Reviews of Infectious Diseases·R HornD Armstrong
Jul 23, 1984·FEBS Letters·E T Sawistowska-SchröderH Perry
Nov 1, 1983·American Journal of Clinical Pathology·W F HickeyF J Schoen
Jul 1, 1980·Antimicrobial Agents and Chemotherapy·J D DickR Saral
Jan 21, 1994·Journal of Medicinal Chemistry·F A BouffardD C McFadden
Jun 1, 1993·The American Journal of Medicine·V SanchezM J Zervos

❮ Previous
Next ❯

Citations

Mar 7, 2013·Applied Microbiology and Biotechnology·Tamás EmriIstván Pócsi
Feb 13, 2001·International Journal of Antimicrobial Agents·J BastertE G Evans
Mar 7, 2002·Cancer Practice·J M Valgus
Dec 11, 1999·Mycoses·J Bastert, H C Korting
Dec 2, 2011·Photochemistry and Photobiology·Antonio RezustaYolanda Gilaberte
Mar 25, 2008·Therapeutics and Clinical Risk Management·Javier PemánMiguel Gobernado
Aug 25, 2004·Clinics in Laboratory Medicine·John W Baddley, Stephen A Moser
Aug 17, 2005·Infectious Disease Clinics of North America·P Brian SmithDaniel K Benjamin
Jan 5, 2002·Mycoses·M Niewerth, H C Korting
Mar 8, 2007·Annals of Saudi Medicine·I Al-Mohsen, W T Hughes
Sep 16, 1998·Antimicrobial Agents and Chemotherapy·G E McElhaney-FeserR L Cihlar
Oct 31, 1998·Antimicrobial Agents and Chemotherapy·E K ManavathuP H Chandrasekar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.